| Patient | Harriet Tubman |
|---|---|
| Date of birth | 1822-03-01 |
| Identifiers | MRN HR-NI005-SYN-TD; SSN (made up) 000-05-3961 |
| Document date | 1897-05-18 |
| Author | Carmen Ruiz-Delgado, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Results of ambulatory EEG and sleep studies; four-week headache check. [S]
Mrs. Tubman returns for her test results and a headache check four weeks after starting candesartan 8 mg. Four of her typical spells were captured during the ambulatory EEG, and the overnight and daytime sleep studies are complete. Her sleep spells continue several times a day. Her headache diary shows fewer headache days than before, though still more than she would like, and she has used acetaminophen about once a week, with no ibuprofen since the first visit. She has had no dizziness on standing, swelling, or cough on candesartan. [S]
| Element | Detail |
|---|---|
| Testing completed | Ambulatory EEG with video, overnight polysomnography, and multiple sleep latency test |
| Sleep spells | Unchanged, several a day |
| Headache diary | Fewer headache days since starting candesartan; partial response |
| Acute medicine | Acetaminophen about once a week; no ibuprofen |
| Candesartan tolerance | No dizziness, swelling, or cough |
| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Sleep spells several times a day; fewer headaches; no weakness or numbness |
| Cardiovascular | Negative | No palpitations, chest pain, or light-headedness on standing |
| Respiratory | Negative | No snoring or witnessed pauses in breathing reported; no cough |
| Psychiatric | Negative | Mood steady; no anxiety about the results |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ibuprofen 200 mg oral tablet, two tablets by mouth most days (self-directed, over the counter) | Two tablets by mouth most days | Oral route | 1896-09-01 to 1897-04-06 | stopped | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth as needed for headache, no more than 2 days a week | Two tablets by mouth as needed, at most 2 days a week | Oral route | 1897-04-06 | active | S |
| Candesartan 8 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1897-04-20 to 1897-05-18 | completed | S |
| Candesartan 16 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1897-05-18 | active | S |
| Modafinil 100 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 1897-05-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1897-05-18 | Body height | 152 | cm | S |
| 1897-05-18 | Body weight | 51.5 | kg | S |
| 1897-05-18 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 1897-05-18 | Systolic blood pressure | 132 | mm[Hg] | S |
| 1897-05-18 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1897-05-18 | Heart rate | 72 | /min | S |
| 1897-05-18 | Respiratory rate | 14 | /min | S |
| 1897-05-18 | Body temperature | 36.6 | Cel | S |
| 1897-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1897-05-18 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 1897-05-18 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1897-05-18 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1897-05-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1892)/1.73 sq M | 67 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1897-05-18 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 1897-05-18 | PROMIS sleep related impairment - version 1.0 Tscore | 67 | {score} | S |
Vital signs recorded on 1897-05-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert; no spell during the visit |
| Cardiovascular | Regular rhythm; no edema |
| Neurological | Nonfocal; gait normal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent sudden sleep episodes since an adolescent traumatic brain injury; narcolepsy without cataplexy due to a medical condition, provisional; historical cause retrospectively disputed | active | provisional | G47.429 | S — Synthetic diagnosis from the modern sleep testing; it echoes, but does not confirm, the R proposal of post-traumatic narcolepsy. |
| Chronic post-traumatic headache since an adolescent head injury | active | confirmed | G44.329 | S — Synthetic modern coding of the documented lifelong headaches. |
| Medication-overuse headache from near-daily ibuprofen, resolved after withdrawal | resolved | confirmed | G44.40 | S — Synthetic finding; resolved by the three-month review. |
| Sequelae of a traumatic brain injury in adolescence, a skull fracture by historical account | active | confirmed | S06.9XAS | S — Synthetic modern coding of the documented injury; the MRI findings in the episode are synthetic. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Ambulatory EEG with video | When routine EEG is not diagnostic | Completed today | Reviewed today: four typical spells captured, each at sleep onset with no ictal pattern |
| Examination | Overnight polysomnography and multiple sleep latency test | For excessive daytime sleepiness | Completed today | Reviewed today: apnea-hypopnea index 4; mean sleep latency 4.5 minutes with two sleep-onset REM periods |
| Medication safety | Antiseizure medicine | Only if spells prove epileptic | Not indicated | Spells are sleep attacks; no antiseizure medicine |
| Survey | PROMIS sleep-related impairment | At baseline and after treatment | Completed today | T-score 67, little changed from 68 before treatment |
| Medication safety | Modafinil: blood pressure and heart rate | Before starting and at follow-up | Completed today | Baseline 132/80 mmHg, pulse 72; started today at 100 mg for an older adult |
| Laboratory | Basic metabolic panel (potassium and creatinine) on candesartan | Before starting and a few weeks after; then periodically | Completed today | Four weeks after starting: potassium 4.6, creatinine 0.90, eGFR 67, sodium and glucose normal |
| Examination | Blood pressure, heart rate, and weight | Every visit | Completed today | 132/80 mmHg, pulse 72, weight 51.5 kg |
| Self-management | Headache diary (headache days and acute-medicine days) | Daily | Completed today | Reviewed; fewer headache days since starting candesartan |
| Medication safety | Acute headache medicine on no more than 2 days a week | Every visit | Completed today | Acetaminophen about once a week; no ibuprofen |
| Survey | Headache days per three months | 2 to 3 months after starting prevention | Due | At the three-month review |
| Self-management | Safety advice for sudden sleep episodes | Every visit | Completed today | Reviewed; scheduled naps added |
| Survey | Depression screen (PHQ-9) | At baseline and at follow-up | Due | At the three-month review |
Goal progress:
Guideline basis: Evidence-based guideline: Management of an unprovoked first seizure in adults (Krumholz A, et al. Neurology 2015;84(16):1705-1713) (2015); Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline (Maski K, et al. J Clin Sleep Med 2021;17(9):1881-1893) (2021); The International Classification of Headache Disorders, 3rd edition (Cephalalgia 2018;38(1):1-211) (2018); The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (Ailani J, et al. Headache 2021;61(7):1021-1039) (2021)
Follow-up: Three-month sleepiness and headache review with potassium and creatinine, PROMIS score, headache-day count, and PHQ-9. Next scheduled visit 1897-08-17: three-month sleepiness and headache review. [S]